← Eichor
Study identifier: NCT05769868 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

Condition: Cirrhosis · Diabetes Mellitus · Oncologic Disorders  ·  Sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER)

PhasePhase 3
Planned participants1000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Tania Luis García, BS  ·  +34 917996034  ·  tanialuisgarcia@cibercv.es

Projects Department (CIBER)  ·  +34 918222874  ·  proyectos@ciberisciii.es

Always discuss trial participation with your own doctor first.

Locations (6)

Hospital Universitari Vall d'HebronBarcelona, Barcelona, SpainRecruiting
Hospital Clínic de BarcelonaBarcelona, Barcelona, SpainNot Yet Recruiting
Hospital General Universitario Gregorio MarañónMadrid, Madrid, SpainRecruiting
Hospital Universitario La PazMadrid, Madrid, SpainRecruiting
Hospital Clínico Universitario de SalamancaSalamanca, Salamanca, SpainRecruiting
Hospital Universitari i Politècnic La FeValencia, Valencia, SpainNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05769868